We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Manufacturers to Add Risks on Labels for Facial Fillers

Manufacturers to Add Risks on Labels for Facial Fillers

June 5, 2015

The FDA is calling for stronger label warnings on facial soft tissue fillers due to the risk of unintentional injection into blood vessels.

The May 28 safety alert warns that the fillers, which are commonly used to lessen the appearance of wrinkles or to make lips and cheeks look fuller, can cause vision problems, stroke or damage to skin and other facial tissue if they are injected into blood vessels.

When this occurs, blood supply to tissue can be restricted or the filler material can travel elsewhere in the body.

The nose, forehead, skin between the eyebrows and nose, and skin around the eyes are especially prone to blood vessel blockage, an FDA literature review shows.

While current labeling on soft tissue fillers mentions the risk of unintentional injection into blood vessels, additional warnings are needed, the agency says. The updated labeling should state that only physicians and others with appropriate training should inject the fillers, and that they should use as little pressure as possible to reduce risk.

Between March 1, 2012, and March 1, 2015, the FDA received 216 adverse event reports related to soft tissue fillers, agency spokesman Eric Pahon says. Of those, 57 described injection into a blood vessel as the cause of the event. Injection into a vessel could not be confirmed in the other 159 reports.

Of the 57 confirmed reports of blood vessel injection, 41 resulted in vision problems, including 32 cases of vision loss or blindness and four cases of stroke.

The remaining 16 involved tissue damage, blockage of blood supply to tissue or whitening of the skin.

The 159 reports of vascular events with unconfirmed injection into a blood vessel included five reports of vision problems, Pahon says. The remaining 154 reports described localized skin reactions, including tissue damage, blockage of blood vessels, whitening of the skin and severe bruising.

According to the American Society of Plastic Surgeons, more than 2.3 million soft tissue filler procedures were performed in 2014.

View the warning at www.fdanews.com/06-08-15-filler.pdf. — Elizabeth Orr

Postmarket Safety

Upcoming Events

  • 10Mar

    FDA Drug GMP Facility Inspections During the Pandemic

  • 16Mar

    Pharmaceutical Naming Regulation: Understanding the Latest Developments

  • 18Mar

    Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 30Mar

    Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

  • 06Apr

    Medical Device Cybersecurity: Understand the Latest Developments

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • Vaccine needle

    Turkish Researchers Downgrade Sinovac’s COVID-19 Vaccine Efficacy Rate

  • Luminex logo

    Luminex Receives EUA for Expanded Respiratory Pathogen Panel, Clearing It for COVID-19

  • Acquires -Acquired

    Amgen to Buy Five Prime Therapeutics for $1.9 Billion

  • abbott-logo.gif

    Abbott Secures EUA for COVID-19 Combination Test

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing